Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
about
Aromatase inhibitors for uterine fibroidsAromatase inhibitors for uterine fibroidsAromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenAromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenEndocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogensOptimal management of hormone receptor positive metastatic breast cancer in 2016Application of metabolomics in drug resistant breast cancer researchAromatase inhibitors and inactivators in breast cancerThe Association of CYP19A1 Variation with Circulating Estradiol and Aromatase Inhibitor Outcome: Can CYP19A1 Variants Be Used to Predict Treatment Efficacy?Breast cancer (metastatic).Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis.Endocrine therapy for gynecological cancer.Altering the estrogenic milieu of breast cancer with a focus on the new aromatase inhibitors.Current and future directions in medical therapy for breast carcinoma: endocrine treatment.An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.FACE: the barefaced facts of AI potency.Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?Anti-tumor effects of letrozole.A roundtable discussion of aromatase inhibitors as therapy for breast cancer.Effect of letrozole on plasma lipids, triglycerides, and estradiol in postmenopausal women with metastatic breast cancerAromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?The discovery and mechanism of action of letrozole.The patient experienceLetrozole in advanced breast cancer: the PO25 trial.Second-line treatment of postmenopausal women with advanced breast carcinoma.Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies.Update on the use of letrozole in breast cancer.The effect of adjuvant hormonal therapy on the endometrium and ovary of breast cancer patients.Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.Letrozole.Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer.Management of patients with metastatic breast cancer.Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review.Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.Aromatase inhibitors and other novel agents in breast cancer treatment.EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancer.Inhibition of oestrogen biosynthesis induces mild anxiety in C57BL/6J ovariectomized female mice.Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early stage breast cancer.Letrozole as primary medical therapy for locally advanced and large operable breast cancer.High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy.
P2860
Q24202922-95A293E0-D456-41A2-9CEB-05CE05621FAEQ24234688-14E883F7-6A86-46C5-B978-F5D090BEDC71Q24239985-2C02BE65-D75F-4136-BA47-A0076C43B3C4Q24246391-AE142D1D-670C-45A4-9FCE-302CCBDE3CAEQ24796233-10E1147A-C678-48F5-8792-C155D360CF42Q26777683-7D5601E0-A68C-4408-A539-D866741F1DD7Q26866291-ED7E2E08-B0A6-4DA8-BDBF-C55F3239EB57Q28362331-66E54AEB-4D47-429C-8713-929FF8D81D75Q30234511-84E58AF9-A014-4319-9AF4-0B4A4714E2FFQ33448016-6E6C46FE-3DB0-4B7F-ABF4-1845DDF7D344Q33698335-4397B2A7-BF9E-4D2A-AB51-3C41AA9235FBQ33843872-B5EC301C-9764-4FCC-8976-C53E32628606Q33871478-9C1D68F7-9829-406F-9950-8047FE1E203CQ33970582-260455E5-9D69-4E3C-BF3A-74C7BEE678B3Q34156603-69509C2E-A872-4375-89E1-6C0FED12E8F0Q34417834-24749E6E-B17D-4284-BC24-EEA78809C06CQ34745884-083BCD31-2AA4-428B-8B38-40EA101F460BQ35004469-4FF6AC00-7D37-4179-BAC8-30DCBD113425Q35129669-93FD8C34-2395-46CF-B502-5E3267CB1B19Q35583799-702A909F-CDD0-445E-870B-249396260151Q35776951-E7FFFA02-ADF7-411E-BD6A-43DF5A08FF52Q36026408-8D24E2C8-5C45-4A2D-B1BA-F7492806A4EEQ36026414-873699A1-B27C-4D95-8B6F-23117A0DAD4AQ36026424-CFE3BED9-1062-43C1-8A99-06331C83A990Q36448699-BFCEA7CB-7AC2-4886-8115-E385FAF7AC77Q36675384-5559B56D-3008-4E9A-8D52-0E13D59F41AAQ36967277-DADCD019-838F-404B-91CA-E4015359E9F6Q37177723-109883A7-1C95-4559-9A06-2DA6579995D7Q37444430-C231171E-12CA-49E3-8CD5-E50F4AD5B8FBQ37679903-5A781D81-7B41-425B-A355-1317B29059D5Q37794991-E37E8880-B8D2-47E3-B151-EA56E6463755Q37933166-08ABF9C4-0A30-4493-B87E-8EE6574962C3Q38239596-9CCC4336-5D86-4FEC-B7CE-2228B27609AFQ39277913-A83FDA1A-30D8-4880-87F1-7247088AC08BQ40409345-54296A41-85E2-471F-8305-907C458CD720Q40761878-BC64CB6D-6856-4A5C-875E-B056BFFC1825Q41442004-D165B737-BE0A-4D30-A96C-0201733842A0Q43267053-14ED47E8-8636-40AC-8211-0816C33CD7C7Q43711061-9EE490A1-6251-4D32-B0B0-EDCCC9647A9FQ43717824-50D26399-7761-4508-A111-9BB775D4BE96
P2860
Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Letrozole, a new oral aromatas ...... national Trial Group (AR/BC3).
@en
Letrozole, a new oral aromatas ...... national Trial Group (AR/BC3).
@nl
type
label
Letrozole, a new oral aromatas ...... national Trial Group (AR/BC3).
@en
Letrozole, a new oral aromatas ...... national Trial Group (AR/BC3).
@nl
prefLabel
Letrozole, a new oral aromatas ...... national Trial Group (AR/BC3).
@en
Letrozole, a new oral aromatas ...... national Trial Group (AR/BC3).
@nl
P2093
P356
P1433
P1476
Letrozole, a new oral aromatas ...... national Trial Group (AR/BC3).
@en
P2093
A Bonaventura
H A Chaudri
M Gershanovich
P304
P356
10.1023/A:1008226721932
P577
1998-06-01T00:00:00Z